Selenium does not affect radiosensitivity of breast cancer cell lines
- 105 Downloads
Supplementation with the antioxidant selenium is frequently performed in breast cancer patients to protect the normal tissue from radiation-induced side effects. However, concerns exist whether selenium also protects tumor cells from radiation-induced cell kill and thereby reduces the efficacy of radiotherapy. In this work, the effect of selenium administration on the radiosensitivity of breast cancer cells was evaluated in vitro. Physiological relevant selenium concentrations (70 and 140 µg/l) did not affect DNA double-strand breaks (γH2AX foci) after 4-Gy X-ray irradiation. Also apoptosis (caspase 3/7) after irradiation with 10 Gy was not influenced by selenium treatment in MDA-MB-231 and MCF7 cells. Most importantly, selenium supplementation did not impair the clonogenic survival of the breast cancer cell lines after irradiation (0, 2, 4, 6, 8 Gy). The data suggest that physiological relevant selenium concentrations administered in combination with radiation therapy do not deteriorate the efficacy of radiotherapy in breast cancer patients. However, randomized clinical trials comparing the effectiveness of radiotherapy and the associated side effects in patients with and without selenium supplementation are recommended.
KeywordsSelenium Radiation Breast cancer Radiosensitivity Antioxidant Supplementation
The authors thank Andrea Mair and Marlon Stein for excellent technical assistance.
This research received no external funding.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- Buntzel J et al (2010) Limited effects of selenium substitution in the prevention of radiation-associated toxicities. Results of a randomized study in head and neck cancer patients. Anticancer Res 30:1829–1832Google Scholar
- Husbeck B, Peehl DM, Knox SJ (2005) Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing. Free Radic Biol Med 38:50–57. https://doi.org/10.1016/j.freeradbiomed.2004.09.022 CrossRefGoogle Scholar
- Micke O, Mucke R, Bruns F, Kisters K, Buntzel J (2007) Some clinical results on selenium in radiation oncology: letter by O. Micke, R. Mucke, F. Bruns, K. Kisters, J. Buntzel on W. Dorr: effects of selenium on radiation responses of tumor cells and tissue—in: Strahlenther Onkol 2006;182:693-5 (No. 12) (https://doi.org/10.1007/s00066-006-1595-8). Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 183:344–345. https://doi.org/10.1007/s00066-007-9595-x CrossRefGoogle Scholar
- Muecke R et al (2014) Multicenter, phase III trial comparing selenium supplementation with observation in gynecologic radiation oncology: follow-up analysis of the survival data 6 years after cessation of randomization. Integr Cancer Ther 13:463–467. https://doi.org/10.1177/1534735414541963 CrossRefGoogle Scholar
- Schilling D, Bayer C, Li W, Molls M, Vaupel P, Multhoff G (2012) Radiosensitization of normoxic and hypoxic h1339 lung tumor cells by heat shock protein 90 inhibition is independent of hypoxia inducible factor-1alpha. PLoS One 7:e31110. https://doi.org/10.1371/journal.pone.0031110 ADSCrossRefGoogle Scholar
- Schueller P, Puettmann S, Micke O, Senner V, Schaefer U, Willich N (2004) Selenium influences the radiation sensitivity of C6 rat glioma cells. Anticancer Res 24:2913–2917Google Scholar
- Shin SH, Yoon MJ, Kim M, Kim JI, Lee SJ, Lee YS, Bae S (2007) Enhanced lung cancer cell killing by the combination of selenium and ionizing radiation. Oncol Rep 17:209–216Google Scholar